These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 11076662

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
    Barret JM, Kruczynski A, Etiévant C, Hill BT.
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
    [Abstract] [Full Text] [Related]

  • 3. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
    Etiévant C, Kruczynski A, Barret JM, Perrin D, van Hille B, Guminski Y, Hill BT.
    Cancer Chemother Pharmacol; 2000 Jun; 46(2):101-13. PubMed ID: 10972479
    [Abstract] [Full Text] [Related]

  • 4. F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells.
    Barret JM, Etiévant C, Baudouin C, Skov K, Charvéron M, Hill BT.
    Anticancer Res; 2002 Jun; 22(1A):187-92. PubMed ID: 12017285
    [Abstract] [Full Text] [Related]

  • 5. Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II.
    Barret JM, Montaudon D, Etiévant C, Perrin D, Kruczynski A, Robert J, Hill BT.
    Anticancer Res; 2000 Jun; 20(6B):4557-62. PubMed ID: 11205304
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
    McRipley RJ, Burns-Horwitz PE, Czerniak PM, Diamond RJ, Diamond MA, Miller JL, Page RJ, Dexter DL, Chen SF, Sun JH.
    Cancer Res; 1994 Jan 01; 54(1):159-64. PubMed ID: 8261436
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS, Clement JJ.
    Cancer Res; 1989 Jun 01; 49(11):2935-40. PubMed ID: 2720652
    [Abstract] [Full Text] [Related]

  • 8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A.
    Cancer Chemother Pharmacol; 2002 Aug 15; 50(2):95-103. PubMed ID: 12172972
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity.
    Bousquet PF, Braña MF, Conlon D, Fitzgerald KM, Perron D, Cocchiaro C, Miller R, Moran M, George J, Qian XD.
    Cancer Res; 1995 Mar 01; 55(5):1176-80. PubMed ID: 7867004
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
    Zhu XK, Guan J, Tachibana Y, Bastow KF, Cho SJ, Cheng HH, Cheng YC, Gurwith M, Lee KH.
    J Med Chem; 1999 Jul 01; 42(13):2441-6. PubMed ID: 10395485
    [Abstract] [Full Text] [Related]

  • 15. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
    MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD.
    Cancer Res; 1997 Jan 15; 57(2):279-83. PubMed ID: 9000568
    [Abstract] [Full Text] [Related]

  • 18. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, Atassi G.
    Cancer Chemother Pharmacol; 1996 Jan 15; 38(6):513-21. PubMed ID: 8823492
    [Abstract] [Full Text] [Related]

  • 19. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, Merlini L, Pisano C, Penco S, Carminati P, Vesci L, Zunino F.
    Clin Cancer Res; 2002 Dec 15; 8(12):3904-9. PubMed ID: 12473606
    [Abstract] [Full Text] [Related]

  • 20. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
    Finch RA, Shyam K, Penketh PG, Sartorelli AC.
    Cancer Res; 2001 Apr 01; 61(7):3033-8. PubMed ID: 11306484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.